MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada’s First Commercial company of Legal, Psychedelic-Assisted, treatment Utilizing Psilocybin

The finished equity investment strengthens ties between MINDCURE and ATMA

VANCOUVER, BC, March 2, 2021 /PRNewswire/ – Mind Cure wellness Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “business”), a frontrunner in developing technology to advance psychedelic-related remedies, is very happy to announce the conclusion of its initial equity that is strategic of equal to approximately 13% ownership in ATMA Journey Centers Inc. (“ATMA”) in accordance with the terms of the letter of intent (the “LOI”) announced on 12, 2021.MINDCURE’s january initial strategic investment of $500,000 will strengthen calgary-based private healthcare company to our relationship, ATMA, which has recently provided psychedelic-assisted therapy sessions using psilocybin for patients with section 56 exemptions.1 MINDCURE will leverage the growing partnership with ATMA to secure a network of clinics in which to deploy and test MINDCURE’s iSTRYM platform, and concurrently, provide MINDCURE with access to patient data accelerating the growth of iSTRYM’s

database. This will lead to better diagnoses, treatments and care that is personalized“Our partnership with ATMA represents a step that is huge for healing today in Canada and around the world. By accelerating the development of our research and technology platform, iSTRYM, we’re closer to minimizing the gaps that exist in health care, all the real way from research to your implementation of care. It is an opportunity that is amazing innovate with pioneers of the psychedelic therapy industry by creating proprietary research, identifying commonalities, and driving real transformative results for individuals using psychedelic medicines,” said Kelsey Ramsden, President & CEO, MINDCURE

.Access to ATMA’s patient data will contribute to MINDCURE’s proprietary technology, iSTRYM

, ultimately helping to optimize treatment for ATMA’s patients and providing a rich data resource for MINDCURE, in accordance with the LOI.“As the first commercial company in Canada to announce legally treating a palliative patient with psychedelic-assisted therapy using psilocybin, we’re optimistic about the progression to better care options for Canadians. By partnering with MINDCURE, we’re enforcing consistency in terms of protocols, as well as the ability to automate patterns in our patients’ conditions. Overall, this will lead to better care that is patient and a stronger foundation because of this revolutionary and leading-edge industry,” said Greg Habstritt, President of ATMA Journey Centers Inc.
“Our objective would be to deliver effective and innovative healing and transformative experiences that leverage the compelling technology around psychedelics. We are focused on supplying the resources, safeguards, expertise, and accessibility into insights which our work reveals, so that you can advocate for better care and treatment that is new.”


“Exemptions,” The Government of Canada (Health Canada, 13, 2020), https://www.canada.ca/en/health-canada/services/health-concerns/controlled-substances-precursor-chemicals/exemptions.html

About november ATMA Journey Centers Inc.

ATMA is a healthcare that is private with the mission of delivering effective and innovative healing and transformative experiences that awaken the inner healer and promote a deeper connection with the self, with others, and with the beauty of the world. ATMA was the first sector that is private provider in Canada to announce performing appropriate psychedelic-assisted treatment for a palliative care client beneath the approval of wellness Canada’s section 56(1) exemption.

The Business has granted a complete of 300,000 commodity to employees that are certain consultants pursuant to the terms the Company’s incentive stock option plan (“Plan”). The stock options are exercisable at a price of $0.63 per subject and share to your regards to the master plan.

About Mind Cure wellness Inc.

MINDCURE exists as an answer to the present health that is mental and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.
MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance health that is mental. MINDCURE is enthusiastic about checking out diverse healing areas beyond psychiatry, including electronic therapeutics, neuro-supports, and psychedelics, all to enhance health that is mental
On Behalf of the Board of Directors

Kelsey Ramsden, President & CEO(*)Forward-Looking that is*)1-888-593-8995

Certain statements in this news launch may represent “forward-looking information” in the meaning of relevant securities rules (also referred to as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such information that is forward-looking. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific information that is forward-looking this news launch includes, it is not restricted to, statements with regards to: strengthening relationship between MINDCURE and ATMA; securing a network of ATMA clinics and use of ATMA’s client information to fuel MINDCURE’s electronic therapeutics platform, iSTRYM; MINDCURE accessing a network of clinics to deploy and test iSTRYM; ATMA conducting further psychedelic-assisted treatment; iSTRYM as well as the relationship with ATMA resulting in better diagnoses, remedies and individualized care; ATMA’s patient information enriching iSTRYM’s database; acceleration associated with growth of iSTRYM.

Forward-looking info is centered on lots of key objectives and presumptions created by MINDCURE, including, without limitation: the COVID-19 impact that is pandemic the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; the partnership with ATMA will help MINDCURE achieve its business goals; ATMA will continue to grow and develop as a provider of clinical services; MINDCURE and ATMA will continue to expand their relationship and negotiate definitive agreements for data access and iSTRYM licensing; and MINDCURE will be able to operate its business as planned. Although the information that is forward-looking in this news launch is situated upon exactly what MINDCURE thinks become reasonable presumptions, it cannot ensure investors that real outcomes will undoubtedly be in line with such information.

Forward-looking info is given to the goal of presenting information regarding administration’s present objectives and plans associated with the long term and readers are cautioned that such statements may possibly not be suitable for other purposes. Forward-looking information involves significant dangers and uncertainties and may never be read as a warranty of future performance or outcomes as real outcomes may vary materially from those expressed or suggested such information that is forward-looking. Those risks and uncertainties include, among other things, risks related to: the impacts of the pandemic that is COVID-19 the Canadian economy, MINDCURE’s industry and MINDCURE’s company, which might adversely affect, and might continue steadily to negatively effect, MINDCURE and might materially adversely influence MINDCURE’s assets, outcomes of operations, economic condition, and MINDCURE’s power to get extra equity or financial obligation funding, and satisfy its obligations; basic economic climates; future development potential; competition for psychological state and health assets; MINDCURE’s partnership with ATMA may well not assist MINDCURE attain its company objectives; and alterations in legislation or laws. Management thinks that the objectives reflected within the forward-looking information included herein are based on reasonable presumptions and information now available; nevertheless, administration will give no assurance that real outcomes will undoubtedly be in line with such information that is forward-looking. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this statement that is cautionary. Forward-looking information reflects administration’s present thinking and it is centered on information now available to MINDCURE. The information that is forward-looking stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

United States Advisory

The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), may be offered and sold outside the United States to investors that are eligible to Regulation S promulgated beneath the U.S. Securities Act, and might never be provided, offered, or resold in the usa or to, or even for the account of or good thing about, a U.S. individual (as a result term is defined in Regulation S beneath the united states of america Securities Act) unless the securities are registered beneath the U.S. Securities Act, or an exemption through the enrollment needs associated with U.S. Securities Act can be acquired. Hedging transactions relating to the securities ought not to be carried out unless according to the U.S. Securities Act. This pr release shall perhaps not represent an offer to offer or the solicitation of an offer to purchase any securities, nor shall there be any purchase of securities within the state in the usa in which offer that is such solicitation or sale would be unlawful.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the accuracy or adequacy with this release.

SOURCE Mind Cure Wellness Inc.

Latest posts

Copyright © 2021 by 99wellness.health. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.